Augmenting Trastuzumab Therapy Against Breast Cancer Through Selective Activation of NK Cells

Abstract

Trastuzumab, a monoclonal antibody (mAb) targeting HER-2/neu, kills tumor cells by several mechanisms, including antibody-dependent cellular cytotoxicity (ADCC). Strategies that enhance the activity of ADCC effectors, including natural killer (NK) cells, may improve trastuzumab s efficacy. NK cells that encounter trastuzumabcoated, HER2-overexpressing breast cancer cells become activated and express CD137, a costimulatory receptor. CD137 activation, which is dependent on the Fc RIII receptor, occurred both in vitro and in the peripheral blood of women with HER2- expressing breast cancer following trastuzumab treatment. Stimulation of trastuzumab-activated NK cells with an agonistic mAb against CD137 killed breast cancer cells more efficiently in vitro.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2012
Accession Number
ADA573699

Entities

People

  • Holbrook Kohrt

Organizations

  • Stanford University

Tags

DTIC Thesaurus Topics

  • Amino Acids Peptides And Proteins
  • Antibodies
  • Biomedical Research
  • Biomolecules
  • Breast Cancer
  • Cancer
  • Cell Line
  • Cells
  • Chemical Compounds
  • Macromolecules
  • Molecules
  • Neoplasms
  • Polymers
  • Proteins
  • Secretion
  • Targeting
  • United States

Fields of Study

  • Biology
  • Medicine

Readers

  • Immunology
  • Prostate Cancer Biology.